Lercanidipine in patients with chronic renal failure: the ZAFRA Study

Lercanidipine in patients with chronic renal failure: the ZAFRA Study

Aim. To evaluate the safe use of a new calcium channel blocker, lercanidipine, in patients with chronic renal failure (CRF); the protective effect of calcium channel blocker on renal function in CRF patients previously treated with ACE inhibitors or angiotensin receptor blockers (ARB). Material and...

Full description

Bibliographic Details
Main Authors: N. R. Robles, J. Ocon, C. F. Gomez, M. Manjon, L. Pastor, J. Herrera, J. Villatoro, J. Calls, J. Torrijos, V. I. Rodríguez, M. M. A. Rodriguez, M. L. Mendez, A. Morey, F. I. Martinez, J. Marco, A. Liebana, B. Rincon, F. Tornero
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2010-08-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
лерканидипин
хроническая почечная недостаточность
гипертензия
Online Access:https://cardiovascular.elpub.ru/jour/article/view/2108

Internet

https://cardiovascular.elpub.ru/jour/article/view/2108

Similar Items